Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Pseudoxanthoma Elasticum Clinical Trial

Official title:

A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05030831
• Other study ID #: INZ701-201
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: April 11, 2022
• Est. completion date: December 5, 2023

Study information

• Verified date: April 2023
• Source: Inozyme Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficiency.

Description:

INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein in development for the treatment of ABCC6 Deficiency, a rare genetic disorder. Study INZ701-201 is a Phase 1/2, multicenter, open-label, multiple ascending dose (MAD), dose-finding study followed by a long-term open-label Extension Period conducted in adults with ABCC6 Deficiency manifesting as Pseudoxanthoma elasticum (PXE). This study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701. The goal of the study is to identify a dose and dose schedule (number of doses per week) for further clinical development. Exploratory endpoints for the Extension Period of the study include evaluations of arterial and organ calcification, ophthalmologic, cardiac and renal parameters, and physical function as well as patient reported outcomes. Subject participation consists of a Screening Period of up to 60 days, a 32-day Dose Evaluation Period, and an Extension Period during which subjects may continue to receive INZ-701 (with options for self-, caregiver-, or healthcare provider administration) until INZ-701 is approved and available in the country where the subject resides or until an alternative study for subjects to continue receiving study drug is available. During the Extension Period, follow-up visits will be conducted every 4 weeks until Week 48, followed by every 12 weeks until the subject leaves the study. Subjects will complete a follow up visit 30 days after their last dose of INZ-701.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: December 5, 2023
• Est. primary completion date: November 7, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria

Individuals eligible to participate must meet all of the following inclusion criteria:

1. Must provide written or electronic consent after the nature of the study has been explained, and prior to any research-related procedures, following International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)

2. Clinical diagnosis of pseudoxanthoma elasticum (PXE) supported by prior genetic identification of biallelic ABCC6 mutations (ie, homozygous or compound heterozygous)

3. Male or female, ages 18 to <70 years of age at Screening

4. PPi <1300 nM at Screening

5. Subjects who are being treated with statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors must have been on treatment for at least 6 months prior to Screening and no new anti-lipid therapy can be introduced within 6 months of Screening

6. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at Screening

7. WOCBP and partners of fertile males who are WOCBP must be using or agree to use one highly effective form of contraception (per CTFG 2020) and a barrier method from at least 1 month before the first dose of INZ-701 through 30 days after the last dose of INZ-701 (greater than 5 half-lives of INZ-701). WOCBP and partners of fertile males who are WOCBP must also agree to not donate ova from the period following the first dose of INZ-701 through 30 days after last dose of INZ-701.

8. Males who are sexually active must agree to use condoms from the period following first dose of INZ-701 through 30 days after the last dose of INZ-701. Males must also agree to not donate sperm from the period following the first dose of INZ-701 through 30 days after last dose of INZ-701.

9. In the opinion of the Investigator, must be willing and able to complete all aspects of the study

10. Agree to provide access to relevant medical records Exclusion Criteria Individuals who meet any of the following exclusion criteria will not be eligible to

participate:

1. In the opinion of the Investigator, presence of any clinically significant disease (outside of those considered associated with the diagnosis of ABCC6 Deficiency) that precludes study participation or may confound interpretation of study results, including known uncontrolled thyroid, or unrelated connective tissue, bone, mineral, lipid, ophthalmologic, or muscle disease

2. Active retinal bleeding in both eyes during Screening

3. Clinically significant abnormal laboratory result at Screening, including but not limited to, eGFR <60 mL/min/1.73m2 (Chronic Kidney Disease-Epidemiology Collaboration equation) and 25-hydroxyvitamin D levels <12 ng/mL

4. Known active fungal, bacterial, and/or viral infection including human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or COVID-19 virus

5. Malignancy within the last 5 years, except non-melanoma skin cancers or cervical carcinoma in situ

6. Known intolerance to INZ-701 or any of its excipients

7. Unable or unwilling to discontinue the use of any prohibited medication. Discontinuation should be undertaken only if considered not detrimental and indicated by the subject's treating physician.

8. Concurrent participation in another non-Inozyme interventional clinical study and/or receipt of any other investigational new drug within 5 half-lives of the last dose of the other investigational drug or from 4 weeks prior to the first dose of INZ-701, whichever is longer, or use of an investigational device through completion of participation in the study

9. Subjects who are pregnant, trying to become pregnant, or breastfeeding

10. Subjects who are trying to father a child

Related Conditions & MeSH terms

• Calcinosis
• Generalized Arterial Calcification of Infancy
• Pseudoxanthoma Elasticum
• Vascular Calcification

Intervention

Drug:
• INZ-701
INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Locations

Country	Name	City	State
United Kingdom	Richmond Pharmacology Ltd (RPL)	London
United States	Clinilabs	Eatontown	New Jersey
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Inozyme Pharma	IQVIA Biotech

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Treatment Emergent Adverse Events (TEAEs)	Treatment-emergent AEs are defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.	32 days (Dose Evaluation Period)
Primary	Number of Treatment Emergent Adverse Events (TEAEs)	Treatment-emergent AEs are defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.	52 weeks (Day 1 through Safety Follow-up Visit)
Secondary	Incidence of Anti-Drug Antibodies (ADAs)	The presence of ADAs will be assessed and, if present, further evaluation will determine specificity and subtypes.	32 days (Dose Evaluation Period)
Secondary	Incidence of Anti-Drug Antibodies (ADAs)	The presence of ADAs will be assessed and, if present, further evaluation will determine specificity and subtypes.	52 weeks (Day 1 through Safety Follow-up Visit)
Secondary	Area under the Plasma Concentration versus Time Curve (AUC) of INZ-701	For each subject, variation of concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	32 days (Dose Evaluation Period)
Secondary	Maximum Plasma Concentration (Cmax) of INZ-701	For each subject, the maximum concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	32 days (Dose Evaluation Period)
Secondary	Systemic Clearance of INZ-701	For each subject, clearance of INZ-701 from the body will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	32 days (Dose Evaluation Period)
Secondary	Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) Levels	For each subject, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	32 days (Dose Evaluation Period)
Secondary	Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) Levels	For each subject, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	52 weeks (Baseline through Safety Follow-up Visit)